Up­dat­ed: Al­ny­lam re­in­forces APOL­LO-B patisir­an da­ta be­fore head­ing to the FDA

Weeks af­ter un­cork­ing some most­ly pos­i­tive da­ta for patisir­an in transthyretin-me­di­at­ed (AT­TR) amy­loi­do­sis with car­diomy­opa­thy, Al­ny­lam is bol­ster­ing its pack­age with new ex­plorato­ry and sub­group da­ta be­fore ship­ping it off to reg­u­la­tors.

The RNAi drug main­tained “gen­er­al­ly con­sis­tent” ben­e­fits in ef­fi­ca­cy and qual­i­ty of life across sev­er­al pre­spec­i­fied sub­groups at month 12, Al­ny­lam an­nounced on Fri­day af­ter­noon, in­clud­ing age, base­line tafamidis use, AT­TR amy­loi­do­sis type, base­line six-minute walk test score and oth­ers.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.